Inclusion criteria |
Adults (both male and female) with nonspecific low back pain for more than three months |
Age range: between 18 and 80 years |
Willingness of the patient to participate in the study, and written informed consent signed and personally dated by the patient |
Chronic nonspecific low back pain clinically diagnosed as repeated lumbar sourness and swelling pain or a chronic progressive process, accompanied by (i) X-ray examination to exclude lumbar vertebrate fractures, spondylolysis, spondylolisthesis and severe osteoporosis, and/or (ii) MRI with normal signal or low nucleus pulposus signal |
No contraindications of rESWT or treatment with celecoxib and eperisone |
Exclusion criteria |
Children and teenagers below the age of 18 |
Elderly aged > 80 years old |
No willingness of the patient to participate in the study, and/or written informed consent not signed and not personally dated by the patient |
Previous spinal fracture or spinal surgery |
Protrusion of a lumbar intervertebral disk, ankylosing spondylitis, scoliosis, lumbar spondylolisthesis and lumbar spondylolysis |
Systemic disorders and psychiatric disorders |
Contraindications of rESWT (pregnancy, presence of blood-clotting disorders (including local thrombosis), presence of local tumors, local bacterial and/or viral infections (including lumbar vertebral tuberculosis), treatment with oral anticoagulants and/or local corticosteroid applications in the period of six weeks before the first rESWT session (if applicable) |
Contraindications of treatment with celecoxib and eperisone (allergy to celecoxib, eperisone or sulfonamides, presence of gastrointestinal bleeding or bleeding history, renal dysfunction and/or severe heart failure, and lactating women) |
Participation in any other clinical trial in the period of 12 weeks before potential inclusion in this study |